Information Provided By: 
Fly News Breaks for May 23, 2019
AXSM
May 23, 2019 | 07:11 EDT
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Axsome Therapeutics to $30 from $23 saying the company recently announced several key positive developments with multiple candidates in its pipeline. The analyst highlights the clarification of a regulatory path forward for AXS-05 in depression, which he believes could culminate in a new drug application filing in 2020. Selvaraju increased his probability of approval for AXS-05 in treatment-resistant depression to 50% from 40% and reiterates a Buy rating on Axsome Therapeutics.
News For AXSM From the Last 2 Days
There are no results for your query AXSM
